[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"saliva-altered\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:saliva-altered":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100648268","salivary-function-and-dental-changes-during-glp-1-therapy-100648268",false,"NCT07720466","Salivary Function and Dental Changes During GLP-1 Therapy","Prospective Evaluation of Salivary Calcium Levels, Salivary Function, and Dental Hard Tissue Changes in Patients Receiving GLP-1 Receptor Agonist Therapy","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Body mass index (BMI) ≥27 kg\u002Fm².\n* Clinical decision by an endocrinologist to initiate semaglutide or tirzepatide therapy for obesity management.\n* No previous treatment with GLP-1 receptor agonists.\n* Willingness to participate and ability to provide written informed consent.\n* Willingness to attend both the baseline and 3-month follow-up visits.\n\nExclusion Criteria:\n\n* Previous use of any GLP-1 receptor agonist.\n* History of head and neck radiotherapy.\n* Sjögren syndrome or other systemic diseases affecting salivary gland function.\n* Chronic kidney disease.\n* Pregnancy or breastfeeding.\n* Use of medications known to markedly affect salivary secretion.\n* Active orthodontic treatment.\n* Severe dental erosion requiring restorative treatment at baseline.\n* Edentulism or the absence of anterior teeth required for dental hard tissue assessment.\n* Inability or unwillingness to comply with the study protocol or attend the 3-month follow-up visit.\n* History of eating disorders associated with recurrent self-induced vomiting (e.g., bulimia nervosa).\n* Medical conditions causing persistent vomiting or severe gastroesophageal disease unrelated to GLP-1 therapy.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","OBSERVATIONAL","People who use glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, may experience changes in their oral health. Some people report dry mouth, changes in saliva, and increased wear of their teeth after starting these medicines. However, little is known about whether these medicines affect saliva and dental hard tissues.\n\nThe purpose of this study is to evaluate changes in salivary calcium levels, salivary function, and dental hard tissues in adults who begin treatment with semaglutide or tirzepatide for obesity.\n\nApproximately 40 participants will be enrolled before starting GLP-1 receptor agonist therapy. Oral examinations, standardized intraoral photographs, saliva samples, and body weight measurements will be obtained before treatment and again after three months. Saliva samples will be analyzed for calcium concentration, pH, and salivary flow rate. Dental hard tissue changes will be assessed using the Basic Erosive Wear Examination (BEWE) index.\n\nThe findings from this study may improve understanding of the effects of GLP-1 receptor agonists on oral health and help healthcare professionals identify and prevent possible dental complications during treatment.",[24,25,26,27],"Obesity","Dental Erosion","Saliva Collection","Saliva Altered","NOT_YET_RECRUITING","2026-07-17",{"date":31,"type":32},"2026-07-22","ACTUAL",{"date":34,"type":20},"2026-08-17",{"date":36,"type":20},"2027-03-17",{"name":38,"class":39},"Bilecik Seyh Edebali Universitesi","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":40},"100640913","application-of-neuro-electrostimulation-as-a-treatment-for-patients-with-dry-mouth-100640913","NCT07593495","Application of Neuro-electrostimulation as a Treatment for Patients With Dry Mouth","Inclusion Criteria:\n\n* Patients diagnosed with dry mouth symptoms.\n* Patients who wish to participate in the study.\n* Patients who allow saliva samples to be collected before, during, and after treatment.\n* Patients who allow the application of transcutaneous electrical nerve stimulation (TENS).\n* Patients who do not have any active oral infections.\n* Patients who attend all sialometry assessments and physiotherapy sessions and complete both quality of life questionnaires (initial and final).\n\nExclusion Criteria:\n\n* Patients with any other mucosal alteration.\n* Patients who do not wish to participate in the study.\n* Patients who do not allow the collection of saliva samples.\n* Patients who do not allow the application of transcutaneous electrical nerve stimulation (TENS).\n* Patients with any infectious process in the oral cavity.\n* Because the study requires the use of low-frequency pulse currents, participants with pacemakers, defibrillators, hearing aids, or cochlear implants will also be excluded from the study.",true,"12 Years","90 Years",{"count":51,"type":20},35,"INTERVENTIONAL",[54],"NA","Hyposalivation is a condition that has increased in frequency, primarily due to the degeneration of salivary glands caused by aging, polypharmacy, chronic or autoimmune diseases, or radiation treatments. Most of these factors are associated with the elderly, a growing demographic due to the aging population. Therefore, addressing this condition has become crucial in our population, as has understanding how it affects their quality of life. Given that saliva plays a vital role in maintaining the oral mucosa, tooth structure, initiating digestion, and even speech, a long-term treatment to stimulate salivary production would be extremely helpful in resolving these problems. Currently, only palliative measures that temporarily cover or lubricate the oral cavity and its structures are available.\n\nAmong the most innovative treatments is neuroelectrical stimulation (TENS) as an adjunct in the therapy of dry mouth, which has shown improvement; however, this improvement has not been quantified through objective measurements that would allow for determining the quantity and quality of saliva, nor in the long term. Likewise, the patient's quality of life affected by this condition has not been assessed.\n\nTherefore, the objective of this project is to evaluate the effect on salivary quality and quantity after the application of neuroelectrical stimulation as a treatment for patients with dry mouth, as well as their quality of life.",[27],[58,59,60,61,62],"Saliva","Salivation","Xerostomia","Quality of life","Physical Therapy Modalities","RECRUITING","2026-05-13",{"date":66,"type":32},"2026-05-18",{"date":68,"type":32},"2026-02-01",{"date":70,"type":20},"2027-07-31",{"name":72,"class":39},"Universidad Autonoma del Estado de Mexico"]